Live Updates: U.S. recommends “pause” for Johnson & Johnson COVID vaccine to review blood clot cases – CBS News

The Centers for Disease Control showed in an alert Tuesday that the Johnson & & Johnson vaccine could resume as quickly as Wednesday. The alert came after a disorderly day when the Food and Drug Administration recommended there be a “pause” for the vaccine, leading virtually every state to halt use of the single-dose shot.
The CDCs Advisory Committee on Immunization Practices will assemble Wednesday for an emergency situation session, with a vote scheduled on “updated recommendations for use” before the group adjourns at 4:30 p.m. ET.
Dr. Anthony Fauci, President Bidens chief medical consultant, informed “CBS Evening News” anchor Norah ODonnell on Tuesday night that it appeared that the adverse impact took place within 6 to 13 days, and “so if youve had it a month or two earlier, I think you actually dont need to stress over anything.”
Fauci highlighted that the chance of these unfavorable side results is “less than 1 in a million,” but he stated to be alert to the signs such as serious headache, some difficulty in motion– such as in a neurological kind of a scenario– or some chest discomfort and difficulty breathing.
Since Monday, more than 6.8 million doses of the Johnson & & Johnson vaccine had been administered across the U.S., a small portion of the general 190 million COVID vaccine shots offered nationwide– the majority of them from Pfizer and Moderna.
The White House stated Tuesday that the pause “will not have a considerable effect” on the nationwide vaccine strategy. President Biden guaranteed Americans that he had actually made sure the U.S. has enough vaccine dosages for all American adults from Pfizer and Moderna alone..
The handful of cases the FDA and CDC are examining occurred in ladies and involved a blood clot called cerebral venous sinus apoplexy, which was seen alongside low levels of blood platelets, according to their statement. Symptoms were seen 6 to 13 days after vaccination in the women, who were between the ages of 18 and 48.
” Treatment of this specific kind of embolism is different from the treatment that may normally be administered. Typically, an anticoagulant drug called heparin is used to treat embolism. In this setting, administration of heparin might threaten, and alternative treatments require to be offered,” they said.
The agencies said the “negative events” seem to be incredibly unusual, but that the time out is necessary so that health care providers can be made conscious of the reactions and appropriately acknowledge and manage the cases, offered the unique treatment required.
Ed OKeefe contributed to this report.

Leave a Reply

Your email address will not be published. Required fields are marked *